These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 20931644)

  • 1. The x-ray structure of the adduct between NAMI-A and carbonic anhydrase provides insights into the reactivity of this metallodrug with proteins.
    Casini A; Temperini C; Gabbiani C; Supuran CT; Messori L
    ChemMedChem; 2010 Dec; 5(12):1989-94. PubMed ID: 20931644
    [No Abstract]   [Full Text] [Related]  

  • 2. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
    Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
    J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: new insights from X-ray diffraction and mass spectrometry studies.
    Casini A; Guerri A; Gabbiani C; Messori L
    J Inorg Biochem; 2008; 102(5-6):995-1006. PubMed ID: 18289690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozyme.
    Messori L; Merlino A
    Dalton Trans; 2014 Apr; 43(16):6128-31. PubMed ID: 24553967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity.
    Liu M; Lim ZJ; Gwee YY; Levina A; Lay PA
    Angew Chem Int Ed Engl; 2010 Feb; 49(9):1661-4. PubMed ID: 20127775
    [No Abstract]   [Full Text] [Related]  

  • 6. Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A.
    Ravera M; Baracco S; Cassino C; Zanello P; Osella D
    Dalton Trans; 2004 Aug; (15):2347-51. PubMed ID: 15278129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and X-ray Structural Analysis of the Ruthenium(III) Complex Na[trans-RuCl4(DMSO) (PyrDiaz)], the Diazene Derivative of Antitumor NAMI-Pyr.
    Vajs J; Pevec A; Gazvoda M; Urankar D; Goreshnik E; Polanc S; Košmrlj J
    Acta Chim Slov; 2017 Dec; 64(4):763-770. PubMed ID: 29318318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of anticancer ruthenium compounds with proteins: high-resolution X-ray structures and raman microscopy studies of the adduct between hen egg white lysozyme and AziRu.
    Vergara A; D'Errico G; Montesarchio D; Mangiapia G; Paduano L; Merlino A
    Inorg Chem; 2013 Apr; 52(8):4157-9. PubMed ID: 23517183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein crystal structures with ferrocene and ruthenocene-based enzyme inhibitors.
    Salmon AJ; Williams ML; Hofmann A; Poulsen SA
    Chem Commun (Camb); 2012 Feb; 48(17):2328-30. PubMed ID: 22258283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osmium NAMI-A analogues: synthesis, structural and spectroscopic characterization, and antiproliferative properties.
    Cebrián-Losantos B; Krokhin AA; Stepanenko IN; Eichinger R; Jakupec MA; Arion VB; Keppler BK
    Inorg Chem; 2007 Jun; 46(12):5023-33. PubMed ID: 17497853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruthenium complexes can target determinants of tumour malignancy.
    Bergamo A; Sava G
    Dalton Trans; 2007 Apr; (13):1267-72. PubMed ID: 17372640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric microtubule disruptors.
    Leese MP; Jourdan F; Kimberley MR; Cozier GE; Thiyagarajan N; Stengel C; Regis-Lydi S; Foster PA; Newman SP; Acharya KR; Ferrandis E; Purohit A; Reed MJ; Potter BV
    Chem Commun (Camb); 2010 May; 46(17):2907-9. PubMed ID: 20386818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
    Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
    J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, structural characterization, solution chemistry, and preliminary biological studies of the ruthenium(III) complexes [TzH][trans-RuCl4(Tz)2] and [TzH][trans-RuCl4(DMSO)(Tz)].(DMSO), the thiazole analogues of antitumor ICR and NAMI-A.
    Mura P; Camalli M; Messori L; Piccioli F; Zanello P; Corsini M
    Inorg Chem; 2004 Jun; 43(13):3863-70. PubMed ID: 15206867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruthenium anticancer drugs.
    Alessio E; Mestroni G; Bergamo A; Sava G
    Met Ions Biol Syst; 2004; 42():323-51. PubMed ID: 15206107
    [No Abstract]   [Full Text] [Related]  

  • 16. NAMI-A preferentially reacts with the Sp1 protein: understanding the anti-metastasis effect of the drug.
    Yuan S; Chen S; Wu H; Jiang H; Zheng S; Zhang Q; Liu Y
    Chem Commun (Camb); 2020 Jan; 56(9):1397-1400. PubMed ID: 31912815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c.
    Casini A; Mastrobuoni G; Terenghi M; Gabbiani C; Monzani E; Moneti G; Casella L; Messori L
    J Biol Inorg Chem; 2007 Nov; 12(8):1107-17. PubMed ID: 17680283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of apo-transferrin with anticancer ruthenium complexes NAMI-A and its reduced form.
    Mazuryk O; Kurpiewska K; Lewiński K; Stochel G; Brindell M
    J Inorg Biochem; 2012 Nov; 116():11-8. PubMed ID: 23010324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbonic anhydrase inhibitors. X-ray crystal studies of the carbonic anhydrase II-trithiocarbonate adduct--an inhibitor mimicking the sulfonamide and urea binding to the enzyme.
    Temperini C; Scozzafava A; Supuran CT
    Bioorg Med Chem Lett; 2010 Jan; 20(2):474-8. PubMed ID: 20005709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, crystal structure, studies in solution and cytotoxicity of two new fluorescent platinum(II) compounds containing anthracene derivatives as a carrier ligand.
    Marqués-Gallego P; den Dulk H; Brouwer J; Kooijman H; Spek AL; Roubeau O; Teat SJ; Reedijk J
    Inorg Chem; 2008 Dec; 47(23):11171-9. PubMed ID: 18975941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.